drugset / Trial / NCT00381381

The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

NCT00381381

Phase 4 Completed 199 enrolled Eisai Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study attempts to differentiate the clinical responses of Choline Acetyltransferase and Apolipoprotein Epsilon gene polymorphism to donepezil in Alzheimer's Disease patients.

Timeline

Start
2006-05-31
Primary completion
2008-08-31
Completion
2008-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 10 mg

Indications